Jeffrey Holford
Stock Analyst at Keybanc
(2.82)
# 1,711
Out of 4,784 analysts
125
Total ratings
70.83%
Success rate
11.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Holford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PH Parker-Hannifin | Maintains: Overweight | $775 → $790 | $601.43 | +31.35% | 1 | Jan 31, 2025 | |
| AZN AstraZeneca | Assumes: Hold | $42 | $73.79 | -43.08% | 3 | Dec 11, 2018 | |
| MRK Merck & Co. | Upgrades: Hold | n/a | $89.23 | - | 30 | Oct 31, 2017 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Hold | n/a | $60.02 | - | 27 | Oct 16, 2017 | |
| JNJ Johnson & Johnson | Upgrades: Buy | n/a | $163.71 | - | 28 | Oct 11, 2017 | |
| ABBV AbbVie | Maintains: Buy | $94 → $107 | $205.29 | -47.88% | 14 | Sep 15, 2017 | |
| LLY Eli Lilly and Company | Maintains: Buy | $89 → $96 | $822.51 | -88.33% | 22 | Sep 15, 2017 |
Parker-Hannifin
Jan 31, 2025
Maintains: Overweight
Price Target: $775 → $790
Current: $601.43
Upside: +31.35%
AstraZeneca
Dec 11, 2018
Assumes: Hold
Price Target: $42
Current: $73.79
Upside: -43.08%
Merck & Co.
Oct 31, 2017
Upgrades: Hold
Price Target: n/a
Current: $89.23
Upside: -
Bristol-Myers Squibb Company
Oct 16, 2017
Downgrades: Hold
Price Target: n/a
Current: $60.02
Upside: -
Johnson & Johnson
Oct 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $163.71
Upside: -
AbbVie
Sep 15, 2017
Maintains: Buy
Price Target: $94 → $107
Current: $205.29
Upside: -47.88%
Eli Lilly and Company
Sep 15, 2017
Maintains: Buy
Price Target: $89 → $96
Current: $822.51
Upside: -88.33%